Health

2021 registered record figures in the realm of corporate venturing.

Harel contributed to drug discovery technology developer Eikon Therapeutics' $518m series B round while a host of corporates are set to exit data management software provider Trifacta in a $400m acquisition.

Nexon has invested $400m in film and television studio Agbo while responsible credit card provider Petal raised $140m in an Encore Bank and Cuna Mutual-backed round.

The digital transformation that has disrupted and reshaped the industrial sector in recent years, known as the fourth industrial revolution or industry 4.0, has now reached a new chapter with the development of what has been dubbed as industry 5.0.

Veon and Prosus helped B2B product marketplace ShopUp push its series B funding to $109m while Sunshine Insurance backed rounds for ImmuneOnco and Xuanzhu Biopharmaceutical.

Baidu Ventures has backed the small molecule cancer therapy developer’s latest round, which came after a slew of healthtech and biotech investments made by the unit in recent months.

Tencent has dodged most of China's regulatory crackdown and built an impressive fintech portfolio globally.

In the second part of our look at the year's corporate venturing trends, we analyse fintech and enterprise bull markets along with some emerging regions.

Data storage technology producer Dera pulled in over $150m through a China Unicom-backed series C round while GlobalBees raised in excess of $110m in a round featuring SoftBank and FirstCry.

Multiple corporates have helped staffing software provider Paradox close a $200m series C round, and electronic parts maker BOE Technology is putting up about $47m in a Chinese state-backed vehicle.

The launch of CIV-LAC as a regional corporate entrepreneurial platform is expected to help 600 startups.